Indications
Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth
Composition
- Active substance
- Beremagene geperpavec
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vyjuvek
- Active substance
- Beremagene geperpavec
- ATC code
- D03AX16
- Group
- Dermatologicals
- Therapeutic area
- Epidermolysis Bullosa Dystrophica
- Marketing authorisation holder
- Krystal Biotech Netherlands B.V.
- Status
- Authorised